RSS feed

Publications by Håkon Wæhre

54 publications found

Original articles

Cyll K, Kleppe A, Kalsnes J, Vlatkovic L, Pradhan M, Kildal W, Tobin KAR, Reine TM, Wæhre H, Brennhovd B, Askautrud HA, Skaaheim Haug E, Hveem TS, Danielsen HE (2021)
PTEN and DNA Ploidy Status by Machine Learning in Prostate Cancer
Cancers (Basel), 13 (17)
DOI 10.3390/cancers13174291, PubMed 34503100

Nunes-Xavier CE, Kildal W, Kleppe A, Danielsen HE, Waehre H, Llarena R, Maelandsmo GM, Fodstad Ø, Pulido R, López JI (2021)
Immune checkpoint B7-H3 protein expression is associated with poor outcome and androgen receptor status in prostate cancer
Prostate, 81 (12), 838-848
DOI 10.1002/pros.24180, PubMed 34125445

Ersvaer E, Hveem TS, Vlatkovic L, Brennhovd B, Kleppe A, Tobin KAR, Pradhan M, Cyll K, Waehre H, Kerr DJ, Danielsen HE (2020)
Prognostic value of DNA ploidy and automated assessment of stroma fraction in prostate cancer
Int J Cancer, 147 (4), 1228-1234
DOI 10.1002/ijc.32832, PubMed 31846064

Ersvær E, Kildal W, Vlatkovic L, Cyll K, Pradhan M, Kleppe A, Hveem TS, Askautrud HA, Novelli M, Wæhre H, Liestøl K, Danielsen HE (2019)
Prognostic value of mitotic checkpoint protein BUB3, cyclin B1, and pituitary tumor-transforming 1 expression in prostate cancer
Mod Pathol, 33 (5), 905-915
DOI 10.1038/s41379-019-0418-2, PubMed 31801961

Kleppe A, Albregtsen F, Vlatkovic L, Pradhan M, Nielsen B, Hveem TS, Askautrud HA, Kristensen GB, Nesbakken A, Trovik J, Wæhre H, Tomlinson I, Shepherd NA, Novelli M, Kerr DJ, Danielsen HE (2018)
Chromatin organisation and cancer prognosis: a pan-cancer study
Lancet Oncol, 19 (3), 356-369
DOI 10.1016/S1470-2045(17)30899-9, PubMed 29402700

Cyll K, Ersvær E, Vlatkovic L, Pradhan M, Kildal W, Avranden Kjær M, Kleppe A, Hveem TS, Carlsen B, Gill S, Löffeler S, Haug ES, Wæhre H, Sooriakumaran P, Danielsen HE (2017)
Tumour heterogeneity poses a significant challenge to cancer biomarker research
Br J Cancer, 117 (3), 367-375
DOI 10.1038/bjc.2017.171, PubMed 28618431

Hveem TS, Kleppe A, Vlatkovic L, Ersvær E, Wæhre H, Nielsen B, Kjær MA, Pradhan M, Syvertsen RA, Nesheim JA, Liestøl K, Albregtsen F, Danielsen HE (2016)
Chromatin changes predict recurrence after radical prostatectomy
Br J Cancer, 114 (11), 1243-50
DOI 10.1038/bjc.2016.96, PubMed 27124335

Sheng X, Arnoldussen YJ, Storm M, Tesikova M, Nenseth HZ, Zhao S, Fazli L, Rennie P, Risberg B, Wæhre H, Danielsen H, Mills IG, Jin Y, Hotamisligil G, Saatcioglu F (2015)
Divergent androgen regulation of unfolded protein response pathways drives prostate cancer
EMBO Mol Med, 7 (6), 788-801
DOI 10.15252/emmm.201404509, PubMed 25864123

Jin Y, Wang L, Qu S, Sheng X, Kristian A, Mælandsmo GM, Pällmann N, Yuca E, Tekedereli I, Gorgulu K, Alpay N, Sood A, Lopez-Berestein G, Fazli L, Rennie P, Risberg B, Wæhre H, Danielsen HE, Ozpolat B, Saatcioglu F (2015)
STAMP2 increases oxidative stress and is critical for prostate cancer
EMBO Mol Med, 7 (3), 315-31
DOI 10.15252/emmm.201404181, PubMed 25680860

Wæhre H, Vlatkovic L, Cvancarova M, Paus E, Fosså SD, Danielsen HE (2013)
Fifteen-year mortality after radical prostatectomy: which factors are available for patient counselling?
Scand J Urol, 48 (2), 123-30
DOI 10.3109/21681805.2013.817483, PubMed 23885810

Kaarbø M, Storm ML, Qu S, Wæhre H, Risberg B, Danielsen HE, Saatcioglu F (2013)
TCTP is an androgen-regulated gene implicated in prostate cancer
PLoS One, 8 (7), e69398
DOI 10.1371/journal.pone.0069398, PubMed 23894469

Wang L, Jin Y, Arnoldussen YJ, Jonson I, Qu S, Maelandsmo GM, Kristian A, Risberg B, Waehre H, Danielsen HE, Saatcioglu F (2010)
STAMP1 is both a proliferative and an antiapoptotic factor in prostate cancer
Cancer Res, 70 (14), 5818-28
DOI 10.1158/0008-5472.CAN-09-4697, PubMed 20587517

Pretorius ME, Waehre H, Abeler VM, Davidson B, Vlatkovic L, Lothe RA, Giercksky KE, Danielsen HE (2009)
Large scale genomic instability as an additive prognostic marker in early prostate cancer
Cell Oncol, 31 (4), 251-9
DOI 10.3233/CLO-2009-0463, PubMed 19633362

Arnoldussen YJ, Lorenzo PI, Pretorius ME, Waehre H, Risberg B, Maelandsmo GM, Danielsen HE, Saatcioglu F (2008)
The mitogen-activated protein kinase phosphatase vaccinia H1-related protein inhibits apoptosis in prostate cancer cells and is overexpressed in prostate cancer
Cancer Res, 68 (22), 9255-64
DOI 10.1158/0008-5472.CAN-08-1224, PubMed 19010898

Klokk TI, Kilander A, Xi Z, Waehre H, Risberg B, Danielsen HE, Saatcioglu F (2007)
Kallikrein 4 is a proliferative factor that is overexpressed in prostate cancer
Cancer Res, 67 (11), 5221-30
DOI 10.1158/0008-5472.CAN-06-4728, PubMed 17545602

Oldenburg J, Alfsen GC, Waehre H, Fosså SD (2006)
Late recurrences of germ cell malignancies: a population-based experience over three decades
Br J Cancer, 94 (6), 820-7
DOI 10.1038/sj.bjc.6603014, PubMed 16508636

Brennhovd B, Johnsrud K, Berner A, Bogsrud T, Waehre H, Giercksky KE, Axcrona K (2006)
Sentinel node procedure in low-stage/low-grade penile carcinomas
Scand J Urol Nephrol, 40 (3), 204-7
DOI 10.1080/00365590600589971, PubMed 16809260

Mu LJ, Kyte JA, Kvalheim G, Aamdal S, Dueland S, Hauser M, Hammerstad H, Waehre H, Raabe N, Gaudernack G (2005)
Immunotherapy with allotumour mRNA-transfected dendritic cells in androgen-resistant prostate cancer patients
Br J Cancer, 93 (7), 749-56
DOI 10.1038/sj.bjc.6602761, PubMed 16136047

Teixeira MR, Ribeiro FR, Eknaes M, Waehre H, Stenwig AE, Giercksky KE, Heim S, Lothe RA (2004)
Genomic analysis of prostate carcinoma specimens obtained via ultrasound-guided needle biopsy may be of use in preoperative decision-making
Cancer, 101 (8), 1786-93
DOI 10.1002/cncr.20527, PubMed 15386312

Fosså SD, Lilleby W, Waehre H, Berner A, Torlakovic G, Paus E, Olsen DR (2003)
Definitive radiotherapy of prostate cancer: the possible role of staging lymphadenectomy
Int J Radiat Oncol Biol Phys, 57 (1), 33-41
DOI 10.1016/s0360-3016(03)00428-0, PubMed 12909213

Oldenburg J, Alfsen GC, Lien HH, Aass N, Waehre H, Fossa SD (2003)
Postchemotherapy retroperitoneal surgery remains necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses
J Clin Oncol, 21 (17), 3310-7
DOI 10.1200/JCO.2003.03.184, PubMed 12947067

Wiig JN, Waehre H, Larsen SG, Braendengen M, Giercksky KE (2003)
Radical prostatectomy for locally advanced primary or recurrent rectal cancer
Eur J Surg Oncol, 29 (5), 455-8
DOI 10.1016/s0748-7983(03)00030-1, PubMed 12798751

Lilleby W, Nesland JM, Fosså SD, Torlakovic G, Waehre H, Kvalheim G (2003)
The prognostic impact of cytokeratin-positive cells in bone marrow of patients with localized prostate cancer
Int J Cancer, 103 (1), 91-6
DOI 10.1002/ijc.10780, PubMed 12455058

Wiig JN, Poulsen JP, Larsen S, Braendengen M, Waehre H, Giercksky KE (2002)
Total pelvic exenteration with preoperative irradiation for advanced primary and recurrent rectal cancer
Eur J Surg, 168 (1), 42-8
DOI 10.1080/110241502317307562, PubMed 12022371

Guren MG, Wiig JN, Dueland S, Tveit KM, Fosså SD, Waehre H, Giercksky KE (2001)
Quality of life in patients with urinary diversion after operation for locally advanced rectal cancer
Eur J Surg Oncol, 27 (7), 645-51
DOI 10.1053/ejso.2001.1195, PubMed 11669593

Teixeira MR, Waehre H, Lothe RA, Stenwig AE, Pandis N, Giercksky KE, Heim S (2000)
High frequency of clonal chromosome abnormalities in prostatic neoplasms sampled by prostatectomy or ultrasound-guided needle biopsy
Genes Chromosomes Cancer, 28 (2), 211-9
DOI 10.1002/(SICI)1098-2264(200006)28:2<211::AID-GCC10>3.0.CO;2-Y, PubMed 10825006

Clobes H, Fossâ SD, Waehre H, Jocham D, Berner A (2000)
The immunohistochemical assessment of occult regional lymph node metastases in patients with T3pN0M0 prostate cancer before definitive radiotherapy
BJU Int, 85 (3), 270-5
DOI 10.1046/j.1464-410x.2000.00406.x, PubMed 10671880

Jacobsen KD, Ous S, Waehre H, Trasti H, Stenwig AE, Lien HH, Aass N, Fosså SD (1999)
Ejaculation in testicular cancer patients after post-chemotherapy retroperitoneal lymph node dissection
Br J Cancer, 80 (1-2), 249-55
DOI 10.1038/sj.bjc.6690347, PubMed 10390004

Fossa SD, Aass N, Ous S, Waehre H, Ilner K, Hannisdal E (1996)
Survival after curative treatment of muscle-invasive bladder cancer
Acta Oncol, 35 Suppl 8, 59-65
DOI 10.3109/02841869609098521, PubMed 9073049

Davidson PJ, Hop W, Kurth KH, Fossa SD, Waehre H, Schröder FH (1995)
Progression in untreated carcinoma of the prostate metastatic to regional lymph nodes (stage t0 to 4,N1 to 3.M0,D1). European Organization for Research and Treatment of Cancer Genitourinary Group
J Urol, 154 (6), 2118-22
DOI 10.1016/S0022-5347(01)66711-9, PubMed 7500472

Josefsen D, Waehre H, Paus E, Fosså SD (1995)
Increase of serum prostatic specific antigen and clinical progression in pN + MO prostate cancer
Br J Urol, 75 (4), 502-6
DOI 10.1111/j.1464-410x.1995.tb07273.x, PubMed 7540482

WARLOE T, PENG Q, HEYERDAHL H, WAEHRE H, MOAN J, STEEN H, GIERCKSKY KE (1995)
PHOTODYNAMIC THERAPY OF HUMAN TUBULO-VILLOUS ADENOMAS
P SOC PHOTO-OPT INS, 2325, 425-436

Opjordsmoen S, Waehre H, Aass N, Fossa SD (1994)
Sexuality in patients treated for penile cancer: patients' experience and doctors' judgement
Br J Urol, 73 (5), 554-60
DOI 10.1111/j.1464-410x.1994.tb07643.x, PubMed 8012779

Fosså SD, Waehre H, Aass N, Jacobsen AB, Olsen DR, Ous S (1993)
Bladder cancer definitive radiation therapy of muscle-invasive bladder cancer. A retrospective analysis of 317 patients
Cancer, 72 (10), 3036-43
DOI 10.1002/1097-0142(19931115)72:10<3036::aid-cncr2820721028>3.0.co;2-b, PubMed 8221571

Waehre H, Ous S, Klevmark B, Kvarstein B, Urnes T, Ogreid P, Johansen TE, Fosså SD (1993)
A bladder cancer multi-institutional experience with total cystectomy for muscle-invasive bladder cancer
Cancer, 72 (10), 3044-51
DOI 10.1002/1097-0142(19931115)72:10<3044::aid-cncr2820721029>3.0.co;2-d, PubMed 8221572

Fosså SD, Berner AA, Jacobsen AB, Waehre H, Kvarstein B, Urnes T, Ogreid P, Johansen TE, Silde J, Nesland JM (1993)
Clinical significance of DNA ploidy and S-phase fraction and their relation to p53 protein, c-erbB-2 protein and HCG in operable muscle-invasive bladder cancer
Br J Cancer, 68 (3), 572-8
DOI 10.1038/bjc.1993.388, PubMed 8102536

Berner A, Nesland JM, Waehre H, Silde J, Fosså SD (1993)
Hormone resistant prostatic adenocarcinoma. An evaluation of prognostic factors in pre- and post-treatment specimens
Br J Cancer, 68 (2), 380-4
DOI 10.1038/bjc.1993.344, PubMed 7688548

Waehre H, Amellem O, Stenwig AE, Tverå K, Juul M, Pettersen EO, Fosså SD (1992)
Deoxyribonucleic acid cytometry and histological findings before and after 125iodine implantation of primary prostate cancer
J Urol, 148 (3), 838-41; discussion 841-2
DOI 10.1016/s0022-5347(17)36737-x, PubMed 1512835

Fosså SD, Waehre H, Paus E (1992)
The prognostic significance of prostate specific antigen in metastatic hormone-resistant prostate cancer
Br J Cancer, 66 (1), 181-4
DOI 10.1038/bjc.1992.239, PubMed 1379059

Fosså SD, Berner A, Waehre H, Heiden T, Juul ME, van den Ouden D, Pettersen EO, Wang N, Tribukait B (1992)
DNA ploidy in cell nuclei from paraffin-embedded material--comparison of results from two laboratories
Cytometry, 13 (4), 395-403
DOI 10.1002/cyto.990130410, PubMed 1526198

Waehre H, Wanderaas EH, Paus E, Fosså SD (1992)
Prediction of pelvic lymph node metastases by a prostate-specific antigen and prostatic acid phosphatase in clinical T3/T4M0 prostatic cancer
Eur Urol, 22 (1), 33-8
DOI 10.1159/000474718, PubMed 1385143

Fosså SD, Nesland JM, Pettersen EO, Amellem O, Waehre H, Heimdal K (1991)
DNA ploidy in primary testicular cancer
Br J Cancer, 64 (5), 948-52
DOI 10.1038/bjc.1991.432, PubMed 1931622

Fosså SD, Nesland JM, Waehre H, Amellem O, Pettersen EO (1991)
DNA ploidy in the primary tumor from patients with nonseminomatous testicular germ cell tumors clinical stage I
Cancer, 67 (7), 1874-7
DOI 10.1002/1097-0142(19910401)67:7<1874::aid-cncr2820670710>3.0.co;2-6, PubMed 1848470

FOSSA SD, AASS N, OUS S, WAEHRE H (1991)
LONG-TERM MORBIDITY AND QUALITY-OF-LIFE IN TESTICULAR CANCER-PATIENTS
Scand. J. Urol. Nephrol. (138), 241-246

Fosså SD, Aass N, Ous S, Waehre H (1991)
Long-term morbidity and quality of life in testicular cancer patients
Scand J Urol Nephrol Suppl, 138, 241-6
PubMed 1785014

Fosså SD, Sager EM, Hosbach G, Waehre H, Ous S (1990)
Cisplatin and medium dose methotrexate in advanced transitional cell carcinoma of the urinary tract
Scand J Urol Nephrol, 24 (3), 199-204
DOI 10.3109/00365599009180858, PubMed 2237296

Fosså SD, Dingsør E, Johannessen NB, Kvarstein B, Stenwig AE, Urnes T, Waehre H, Ogreid P (1987)
Pre-cystectomy chemotherapy in patients with muscle infiltrating bladder carcinoma. A multicentre feasibility study
Scand J Urol Nephrol, 21 (1), 39-42
DOI 10.3109/00365598709180288, PubMed 3589522

Fryjordet A, Waehre H (1982)
[Peripheral infiltrating cancer of the renal pelvis]
Tidsskr Nor Laegeforen, 102 (7), 428-9
PubMed 7157303

Nordshus T, Vinje B, Waehre H (1980)
[Urography and urethrocystography in patients with suspected prostatic hyperplasia]
Tidsskr Nor Laegeforen, 100 (30), 1765-7
PubMed 6161423

Normann E, Waehre H (1979)
[Primary vesico-ureteral reflux in adults]
Tidsskr Nor Laegeforen, 99 (32), 1638-40
PubMed 531842

Review articles

Lilleby W, Hernes E, Waehre H, Raabe N, Fosså SD (2006)
[Treatment of hormone-resistant prostate cancer]
Tidsskr Nor Laegeforen, 126 (21), 2798-801
PubMed 17086220

Norderhaug I, Dahl O, Høisaeter PA, Heikkilä R, Klepp O, Olsen DR, Kristiansen IS, Waehre H, Bjerklund Johansen TE (2003)
Brachytherapy for prostate cancer: a systematic review of clinical and cost effectiveness
Eur Urol, 44 (1), 40-6
DOI 10.1016/s0302-2838(03)00187-8, PubMed 12814673

Norderhaug I, Johansen TB, Dahl O, Høisaeter PA, Heikkilä R, Klepp O, Olsen DR, Kristiansen IS, Waehre H (2002)
[Brachytherapy in prostatic cancer]
Tidsskr Nor Laegeforen, 122 (29), 2795-8
PubMed 12523149

Other articles

Kaarbø M, Storm ML, Qu S, Wæhre H, Risberg B, Danielsen HE, Saatcioglu F (2015)
Correction: TCTP is an androgen-regulated gene implicated in prostate cancer
PLoS One, 10 (5), e0128727
DOI 10.1371/journal.pone.0128727, PubMed 25973603